stockrowTwist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) Shares outstanding
Twist Bioscience Corporation's shares outstanding at the end of fiscal 2025 was $59.8M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $62.4M. Over the past ten years it has ranged from $1.9M (fiscal 2016) to $59.8M (fiscal 2025) — the current reading is the highest in ten years. Twist Bioscience Corporation ranks 248th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $59.8M | 3.09% |
| FY2024 | $58.0M | 1.99% |
| FY2023 | $56.9M | 5.57% |
| FY2022 | $53.9M | 11.68% |
| FY2021 | $48.3M | 23.12% |
| FY2020 | $39.2M | 42.71% |
| FY2019 | $27.5M | 883.24% |
| FY2018 | $2.8M | 15.32% |
| FY2017 | $2.4M | 29.52% |
| FY2016 | $1.9M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $62.4M | 1.14% |
| Mar 2026 | $61.7M | 1.02% |
| Dec 2025 | $61.1M | 2.13% |
| Sep 2025 | $59.8M | (2.22%) |
| 31 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| TWST Twist Bioscience Corporation | $62.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on TWST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement